🏛️ Verified NIH Record • Updated 2023-11-21
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (NCT05270044)
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Pierre Fabre Medicament
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).
Who can join: Review the eligibility criteria below.
Location: Centro Oncologico Korben — CABA, Buenos Aires
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (155 Sites)
Showing the first 25 of 155 sites.
- Centro Oncologico Korben — CABA, Buenos Aires
- Centro de Investigaciones Medicas Mar del Plata — Mar del Plata, Buenos Aires
- Fundacion CIDEA — Ciudad Autonoma Bs As, Ciudad Autonoma Buenos Aires
- Sanatorio Britanico S.A. — Rosario, Santa Fe Province
- Instituto de Oncologia de Rosario — Rosario, Santa Fe Province
- Hospital Aleman — Ciudad Autonoma Buenos Aires,
- Instituto Medico Especializado Alexander Fleming — Ciudad Autonoma Buenos Aires,
- Clinica Adventista Belgrano — Ciudad Autonoma Buenos Aires,
- Westmead Hospital — Sydney, New South Wales
- Melanoma Institute Australia — Wollstonecraft, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Adelaide Oncology & Haematolog, Calvary North Adelaide Hospital — North Adelaide, South Australia
- Box Hill Hospital — Box Hill, Victoria
- Austin Health — Heidelberg, Victoria
- The Alfred Hospital — Prahran, Victoria
- Hollywood Private Hospital — Nedlands, Western Australia
- Sir Charles Gairdner Hospital — Nedlands, Western Australia
- Landeskrankenhaus - Universitaetsklinikum Graz — Graz,
- Krankenhaus der Elisabethinen Linz — Linz,
- Universitätsklinikum St.Pölten-Lilienfeld — Sankt Pölten,
- AKH - Medizinische Universität Wien — Vienna,
- Institut Jules Bordet — Anderlecht,
- ZNA Middelheim — Antwerp,
- Universitair Ziekenhuis Brussel — Brussels,
- Cliniques Universitaires Saint-Luc — Brussels,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.